We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1551
Hovnanian Enterprises
HOV
$797M
| $712K | ﹤0.01% |
16,645
+5,511
| +49% | +$268K |
|
1552
Boston Beer
SAM
$1.84B
| $712K | ﹤0.01% |
2,362
+411
| +21% | +$143K |
|
1553
Teekay
TK
$959M
| $712K | ﹤0.01% |
247,242
-71,239
| -22% | -$233K |
|
|
PAMT
1554
PAMT Corp
PAMT
$284M
| $708K | ﹤0.01% |
25,849
+8,973
| +53% | +$253K |
|
|
KBAL
1555
DELISTED
Kimball International
KBAL
| $706K | ﹤0.01% |
92,031
+1,749
| +2% | +$14.3K |
|
|
MNRL
1556
DELISTED
Brigham Minerals, Inc. Class A Common Stock
MNRL
| $702K | ﹤0.01% |
28,488
-5,906
| -17% | -$163K |
|
1557
Resideo Technologies
REZI
$3.68B
| $699K | ﹤0.01% |
35,989
-18,363
| -34% | -$414K |
|
1558
Helen of Troy
HELE
$686M
| $697K | ﹤0.01% |
4,487
-3,831
| -46% | -$722K |
|
|
ROCC
1559
DELISTED
Ranger Oil Corporation Class A Common Stock
ROCC
| $696K | ﹤0.01% |
21,163
+8,435
| +66% | +$318K |
|
1560
Marten Transport
MRTN
$1.19B
| $695K | ﹤0.01% |
41,341
-9,575
| -19% | -$165K |
|
|
VRAY
1561
DELISTED
ViewRay, Inc.
VRAY
| $691K | ﹤0.01% |
260,846
+25,711
| +11% | +$77.4K |
|
|
EMBJ
1562
Embraer S.A. ADS
EMBJ
$12.8B
| $689K | ﹤0.01% |
+78,462
| New | +$839K |
|
1563
Adaptive Biotechnologies
ADPT
$4.1B
| $688K | ﹤0.01% |
87,870
-75,420
| -46% | -$663K |
|
1564
HNI Corp
HNI
$3.61B
| $688K | ﹤0.01% |
19,833
-97
| -0.5% | -$3.52K |
|
|
AD
1565
Array Digital Infrastructure
AD
$3.05B
| $688K | ﹤0.01% |
23,897
+5,268
| +28% | +$158K |
|
1566
CarGurus
CARG
$3.26B
| $686K | ﹤0.01% |
31,902
+7,260
| +29% | +$215K |
|
1567
Hawkins
HWKN
$2.74B
| $684K | ﹤0.01% |
18,996
-2,113
| -10% | -$79.9K |
|
1568
Acadia Realty Trust
AKR
$2.79B
| $681K | ﹤0.01% |
43,568
-6,087
| -12% | -$117K |
|
1569
iHeartMedia
IHRT
$476M
| $680K | ﹤0.01% |
86,133
-4,969
| -5% | -$67K |
|
1570
Syndax Pharmaceuticals
SNDX
$1.81B
| $680K | ﹤0.01% |
35,358
+11,607
| +49% | +$193K |
|
1571
Badger Meter
BMI
$3.97B
| $677K | ﹤0.01% |
8,365
+383
| +5% | +$31.7K |
|
1572
Phibro Animal Health
PAHC
$1.4B
| $672K | ﹤0.01% |
35,134
+11,487
| +49% | +$218K |
|
1573
Douglas Dynamics
PLOW
$985M
| $669K | ﹤0.01% |
23,263
+4,314
| +23% | +$134K |
|
|
CIR
1574
DELISTED
CIRCOR International, Inc
CIR
| $667K | ﹤0.01% |
+40,725
| New | +$815K |
|
1575
Acadia Pharmaceuticals
ACAD
$5.11B
| $666K | ﹤0.01% |
47,264
+8,296
| +21% | +$155K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.